- Global Pharma News & Resources

Non-Muscle Invasive Bladder Cancer (NMIBC) Market is increasing with ~ 8% CAGR during the study period (2017-2030), according to DelveInsight

The factors like the expected entry of emerging therapies with novel targets and pricing are fueling the market. Also, upcoming products such as Adstiladrin, Vicinium, N-803, TLD-1433, CG0070 and Keytruda are anticipated to expand the market.

LAS VEGAS, Oct. 5, 2020 /PRNewswire/ -- DelveInsight's latest report on Non-Muscle Invasive Bladder Cancer  Market also indicates that the tremendous growth of market size is because of the increased incident cases of NMIBC, imminent drug launches, increased diagnosis, upsurge in research and development, and enriched understanding of the disease.   

Some key highlights from the report:

  • In the 7MM, the total diagnosed prevalent population of NMIBC was estimated to be 533,263 cases in 2017, which is expected to increase in the forecast period
  • The United States accounted for the maximum diagnosed prevalent population among the 7MM in 2017.
  • The United States also accounted for more than half (50.69%) of the market share in the 7MM.
  • Adstiladrin is projected to lead the market with the largest market share in 2030.
  • Non-Muscle Invasive Bladder Cancer Key Players are Sesen Bio, FKD Therapies Oy, Ferring Pharmaceuticals, Hoffmann-La Roche, Pfizer, Spectrum Pharmaceuticals, Bristol-Myers Squibb, AstraZeneca, UroGen Pharma, Incyte Corporation, CG Oncology, Janssen Research & Development, Celgene Corporation, ImmunityBio, Altor Biosciences, Theralase, EMD Serono, Hamlet Pharma, TesoRx Pharma, AstraZeneca and others. 

Discover more here:-

Non-Muscle Invasive Bladder Cancer is a common, heterogeneous disease associated with high recurrence rates. The cancer is found in the tissue that lines the bladder's inner surface, wherein the bladder muscle is not involved.

Approximately 70–80% of patients with newly diagnosed bladder cancer present with a form of Non-Muscle Invasive Bladder Cancer, such as non-invasive papillary tumour (pTa), carcinoma in situ (CIS; pTis), or early invasive tumour (non-muscle invasive; pT1). These tumours characteristically recur in 50–70% of cases, with only approximately 10–20% of cases progressing to muscle-invasive bladder cancer (MIBC).

The epidemiology for NMBIC is complex however DelveInsight's NMIBC report covers an in-depth epidemiological analysis and provides epidemiological forecasts upto 2030, segmented as the following: ·  Prevalent cases of Bladder Cancer

  • Diagnosed Prevalent cases of Bladder Cancer
  • Diagnosed Prevalent cases of NMIBC
  • Age-specific Diagnosed Prevalence of NMIBC
  • Tumour (T) stage specific Diagnosed Prevalence of NMIBC
  • Grade-specific Diagnosed Prevalence of NMIBC
  • Risk-specific Diagnosed Prevalence of NMIBC

Non-Muscle Invasive Bladder Cancer Market Scenario

NMIBC remains a very challenging disease to treat with high rates of recurrence and progression associated with current therapies. The high rates of progression and recurrence with current therapies for NMIBC necessitate lifelong active surveillance, making bladder cancer the most expensive cancer to treat from diagnosis to death, as well as driving the need for the development of new therapies in patients with NMIBC.

Historically Bacillus Calmette–Guarin (BCG) was the main treatment option for early bladder cancer i.e. high-risk NMIBC but more than 50-60% of patients become BCG unresponsive. Additionally, ongoing BCG shortage in addition to the lack of effective alternative drug therapies for patients with BCG-unresponsive disease, a large unmet need exists for these patients and providers. The treatment regimen includes surgery, intravesical immunotherapy, and intravesical chemotherapy. Intermediate- or high-risk NMIBC is generally treated with transurethral resection of bladder tumor (TURBT), followed by adjuvant BCG immunotherapy, which is the standard gold treatment for reducing tumor recurrence rates and preventing subsequent stage progression. However these are associated with many adverse side effects.  Due to all these issues, there was a high unmet need for these patients until Keytruda got approved in 2020. Newer promising agents including gene therapies and fusion proteins are in pipeline, addressing these challenges. The high-grade NMIBC pipeline possesses potential drugs in mid and late stage developments to be launched in the near future.  Some of the potential ones are:

Adstiladrin (nadofaragene firadenovec):  is a gene therapy consisting of an adenovirus containing the gene interferon (IFN)-alpha2b. Things are on track for approval of gene therapy for early-stage bladder cancer i.e. High-risk BCG refractory NMIBC sooner as the latest data presented during ASCO GU symposium 2020 was very promising and even better in terms of efficacy and duration of response than only approved treatment i.e. Keytruda. It has got Priority Review; Fastrack; Breakthrough designation from USFDA already.

Keytruda: It is the first and only approved immune checkpoint inhibitor approved for high-risk non-muscle-invasive bladder cancer. It is expected to get stiff competition from Adstiladrin, a gene therapy that will share the same patient pool with Keytruda.

Vicinium: also known as VB4-845, is an antibody-drug conjugate (ADC), developed for the treatment of high-grade non-muscle invasive bladder cancer (NMIBC). Vicinium is comprised of a recombinant fusion protein that targets epithelial cell adhesion molecule (EpCAM) antigens on the surface of tumor cells to deliver a potent protein payload, Pseudomonas Exotoxin A (ETA).

N-803 (ALT-803):  is an interleukin-15 (IL-15) agonist, along with BCG looks another promising option for NMIBC patients

Emerging Drugs in NMIBC | Key Players involved

  1. Vicinium: Sesen Bio
  2. Adstiladrin (nadofaragene firadenovec/Syn3): FKD Therapies Oy/ Ferring Pharmaceuticals
  3. Tecentriq (atezolizumab): Hoffmann-La Roche
  4. Sasanlimab (PF-06801591) + BCG: Pfizer
  5. Apaziquone: Spectrum Pharmaceuticals
  6. Opdivo (nivolumab): Bristol-Myers Squibb
  7. Imfinzi (durvalumab): AstraZeneca
  8. VesiGel (UGN-102/mitomycin gel): UroGen Pharma
  9. Pemigatinib: Incyte Corporation
  10. CG0070: CG Oncology
  11. Erdafitinib: Janssen Research & Development
  12. Revlimid (lenalidomide): Celgene Corporation/Bristol-Myers Squibb
  13. N-803 (ALT-803): ImmunityBio/Altor Biosciences
  14. TLD-1433: Theralase
  15. Bavencio (avelumab + BCG): EMD Serono
  16. Alpha1H: Hamlet Pharma
  17. LiPax: TesoRx Pharma
  18. Imfinzi (durvalumab) + S-488210/S-488211: AstraZeneca

Key Trends of Non-Muscle Invasive Bladder Cancer Market Report: 

Scope of the Report

  • Geography Covered: 7MM - The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan.
  • Study Period: 3-year historical and 11-year forecasted analysis (2017-2030).
  • Markets Segmentation: By Geographies, By Therapies (Forecasted + Historical).
  • Companies Covered: Sesen Bio, FKD Therapies Oy, Ferring Pharmaceuticals, Hoffmann-La Roche, Pfizer, Spectrum Pharmaceuticals, Bristol-Myers Squibb, AstraZeneca, UroGen Pharma, Incyte Corporation, CG Oncology, Janssen Research & Development, Celgene Corporation, ImmunityBio, Altor Biosciences, Theralase, EMD Serono, Hamlet Pharma, TesoRx Pharma, AstraZeneca and several others.
  • Analysis: Comparative and conjoint analysis of emerging therapies, Attribute Analysis
  • Case Studies
  • KOL's Views
  • Analyst's View

Table of Contents

1 Key Insights

2 Executive Summary of Non-Muscle Invasive Bladder Cancer

3 Non-Muscle Invasive Bladder Cancer SWOT Analysis

4 Non-Muscle Invasive Bladder Cancer Market Overview at a Glance

5 Disease Background and Overview: Non-Muscle Invasive Bladder Cancer

6 Recognized Establishments

7 Non-Muscle Invasive Bladder Cancer Epidemiology and Patient Population

8 7MM Total Diagnosed NMIBC Prevalent cases 

9 7MM NMIBC Epidemiology

9.1 United States

9.2 EU5 Countries

9.3 Germany

9.4 France

9.5 Italy

9.6 Spain

9.7 United Kingdom

9.8 Japan

10 Non-Muscle Invasive Bladder Cancer Treatment

11 Unmet Needs

12 Non-Muscle Invasive Bladder Cancer Marketed Drugs

12.1 Keytruda (pembrolizumab): Merck

12.2 Valstar (valrubicin): Endo Pharmaceuticals

13 Non-Muscle Invasive Bladder Cancer Emerging Drugs

13.1 Vicinium: Sesen Bio

13.2 Adstiladrin (nadofaragene firadenovec/Syn3): FKD Therapies Oy/ Ferring Pharmaceuticals

13.3 Tecentriq (atezolizumab): Hoffmann-La Roche

13.4 Sasanlimab (PF-06801591) + BCG: Pfizer

13.5 Apaziquone: Spectrum Pharmaceuticals

13.6 Opdivo (nivolumab): Bristol-Myers Squibb

13.7 Imfinzi (durvalumab): AstraZeneca

13.8 VesiGel (UGN-102/mitomycin gel): UroGen Pharma

13.9 Pemigatinib: Incyte Corporation

13.10 CG0070: CG Oncology

13.11 Erdafitinib: Janssen Research & Development

13.12 Revlimid (lenalidomide): Celgene Corporation/Bristol-Myers Squibb

13.13 N-803 (ALT-803): ImmunityBio/Altor Biosciences

13.14 TLD-1433: Theralase

13.15 Bavencio (avelumab + BCG): EMD Serono

13.16 Alpha1H: Hamlet Pharma

13.17 LiPax: TesoRx Pharma

13.18 Imfinzi (durvalumab) + S-488210/S-488211: AstraZeneca

14 Non-muscle Invasive Bladder Cancer 7 Major Market Analysis

15 Attribute Analysis

16 Key Non-Muscle Invasive Bladder Cancer Market Assumptions

17 7MM NMIBC Market Outlook

17.1 United States NMIBC Market Size

17.2 Germany

17.3 France

17.4 Italy

17.5 Spain

17.6 United Kingdom

17.7 Japan NMIBC Market Size

18 Access and Reimbursement

19 Case Reports

20 Non-Muscle Invasive Bladder Cancer Market Drivers

21 Non-Muscle Invasive Bladder Cancer Market Barriers

22 Appendix

23 DelveInsight Capabilities

24 Disclaimer

25 About DelveInsight


Browse Detailed TOC, Tables, Figures, Emerging Drugs and Companies @ 

Reasons to buy

  • The report helps in development of business strategies by understanding trends.
  • Insights on future market competition in the Non-Muscle Invasive Bladder Cancer market.
  • Organize sales and marketing efforts by identifying the best opportunities for NMIBC.
  • Identification of strong upcoming players in the market to stay ahead of competitors.

Request a WebEx Walkthrough of the Report: 

Related Reports

Non Muscle Invasive Bladder Cancer Pipeline Insights, 2020

Non Muscle Invasive Bladder Cancer Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur


Non-Muscle Invasive Bladder Cancer (NMIBC) Market is increasing with ~ 8% CAGR during the study period (2017-2030), according to DelveInsight

Editor Details

Last Updated: 05-Oct-2020